We don't know whether the most recent response to this request contains information or not – if you are Oliver Caswell please sign in and let everyone know.

metastatic Cholangiocarcinoma (CCA) and Acute myeloid leukaemia (AML)

Oliver Caswell made this Freedom of Information request to Grampian Health Board as part of a batch sent to 216 authorities This request has been closed to new correspondence. Contact us if you think it should be reopened.

We're waiting for Oliver Caswell to read a recent response and update the status.

Oliver Caswell
Delivered

Dear Grampian Health Board,

Please can I request answers relating to the below questions. A national collation of this information will be made available to any trust requesting it in reply.

1. How many patients in the last 12 months has the trust treated for metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia (AML)?
a. For each of AML and CCA, how many have IDH-1 mutation?
b. How many CCA are intrahepatic vs extrahepatic?
i. How many of each of these present at 2nd line? How many of these at 2nd line have IDH-1 mutation?
c. For AML, how many patients were not fit for intensive chemotherapy? How many of these AML patients have IDH-1 mutation?

2. How many patients have been treated with pemigatinib (CCA), venetoclax plus azacitadine dual therapy or azacitadine monotherapy (AML )?
a. What is the average treatment duration for CCA patients treated with pemigatinib and AML patients treated with azacitadine dual therapy and azacitadine monotherapy? What is the preferred azacitadine product?

3. What is the real-world dosing for venetoclax (in combination with a CYP3A4)?
a. What is the antifungal of choice for patients treated with venetoclax?
b. What is the antifungal average treatment duration when used in combination with venetoclax ?
c) what proportion of patients are treated with an antifungal in combination with venetoclax? In what proportion of patients is the antifungal treatment stopped? In what proportion of these pts is the venetoclax dosage altered following cessation of the antifungal?

4. Do you routinely test CCA and AML patients for IDH-1 mutation?
a. If so when does the testing take place. E.g. at diagnosis or following 1st line progression? Is this done using NGS panel? Is this done using PCR testing?
B. What is the average turnaround time for these tests?

5. Who is responsible for the routine management of patients with CCA and AML?
a. Clinical oncologist / medical oncologist / specialist nurse etc?

6. How many admissions have occurred in the last 12 months for patients with CCA and AML?
a. What is their average length of stay?
b. How many of these patients were readmissions or readmitted during this time? If readmitted, can you state the main reason?

Thank you for taking the time to supply this information.

Yours faithfully,

Oliver Caswell

Link to this Report
GRAM Foi, Grampian Health Board

Dear Mr Caswell,

 

Freedom of Information (Scotland) Act 2002

 

Thank you for your email dated 6 September 2022, requesting information
regarding cancer treatment at NHS Grampian. We have recorded this request
and are currently processing it in accordance with the Freedom of
Information (Scotland) Act 2002.

 

A response to your request for information is due by 5 October 2022.
Please allow for delivery time.

 

We will contact you again in due course.

 

Best wishes,

 

Susie

 

Susie Nattrass

Information Governance Officer

Information Governance Team

 

NHS Grampian

Rosehill House

Cornhill Road

Aberdeen

AB25 2ZG

 

Phone: 01224 551549

[1][NHS Grampian request email]

 

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------
This email is intended for the named recipient only. If you have received
it by mistake,
please (i) contact the sender by email reply; (ii) delete the email from
your system; .
and (iii) do not copy the email or disclose its contents to anyone.

--------------------------------------------------------------------------------------------------------------------------------------------------------

References

Visible links
1. mailto:[NHS Grampian request email]

Link to this Report
GRAM Foi, Grampian Health Board

1 Attachment

Dear Mr Caswell,

 

Please find attached the response to your request.

 

Please accept my apologies for the delay in providing this response and
any inconvenience this may have caused. There have been to a high volume
of requests received by our team, and a number of historic requests for
information which we are currently working our way through.

 

Kind Regards

 

Lynsey

Senior Information Governance Officer

 

Information
Governance Team NHS Grampian
Rosehill
  House

[1][NHS Grampian request email] Cornhill Road
Aberdeen
Phone : 01224 551319
AB25 2ZG
                 ext
51319

 

 

 

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------
This email is intended for the named recipient only. If you have received
it by mistake,
please (i) contact the sender by email reply; (ii) delete the email from
your system; .
and (iii) do not copy the email or disclose its contents to anyone.

--------------------------------------------------------------------------------------------------------------------------------------------------------

References

Visible links
1. mailto:[NHS Grampian request email]

Link to this Report
We don't know whether the most recent response to this request contains information or not – if you are Oliver Caswell please sign in and let everyone know.